9th May 2022 16:37
9 May 2022
Diaceutics PLC
("Diaceutics", the "Company" or the "Group")
Exercise of Warrant & Total Voting Rights
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it has received notification for the exercise of a warrant over 170,000 ordinary shares in the Company at an exercise price of £0.76 per share providing the Company with proceeds of £129,200 ("Warrant Exercise").
Application has been made to the London Stock Exchange to admit the 170,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM ("Admission"), which is expected to occur on 13 May 2022. The new ordinary shares will rank pari passu with the existing ordinary shares.
Following Admission, the total issued share capital of the Company will consist of 84,472,431 Ordinary Shares of £0.002 each. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Diaceutics PLC | |
Nick Roberts, Chief Financial Officer | Via Alma PR |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Stewart Wallace | |
Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | |
Kieran Breheny | |
Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Related Shares:
Diaceutics